- Home
- GLUE vs EAF Comparison
GLUE vs EAF Comparison
Compare GLUE & EAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- EAF
- Stock Information
- Founded
- GLUE 2019
- EAF 1886
- Country
- GLUE United States
- EAF United States
- Employees
- GLUE N/A
- EAF N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- EAF Industrial Machinery/Components
- Sector
- GLUE Health Care
- EAF Energy
- Exchange
- GLUE Nasdaq
- EAF Nasdaq
- Market Cap
- GLUE 308.8M
- EAF 342.1M
- IPO Year
- GLUE 2021
- EAF 1995
- Fundamental
- Price
- GLUE $12.50
- EAF $13.08
- Analyst Decision
- GLUE Buy
- EAF Hold
- Analyst Count
- GLUE 2
- EAF 6
- Target Price
- GLUE $13.50
- EAF $17.00
- AVG Volume (30 Days)
- GLUE 1.2M
- EAF 294.0K
- Earning Date
- GLUE 11-07-2025
- EAF 10-24-2025
- Dividend Yield
- GLUE N/A
- EAF N/A
- EPS Growth
- GLUE N/A
- EAF N/A
- EPS
- GLUE 0.29
- EAF N/A
- Revenue
- GLUE $177,986,000.00
- EAF $521,894,000.00
- Revenue This Year
- GLUE $66.94
- EAF N/A
- Revenue Next Year
- GLUE N/A
- EAF $24.19
- P/E Ratio
- GLUE $42.49
- EAF N/A
- Revenue Growth
- GLUE 2990.57
- EAF N/A
- 52 Week Low
- GLUE $3.50
- EAF $5.50
- 52 Week High
- GLUE $12.97
- EAF $25.30
- Technical
- Relative Strength Index (RSI)
- GLUE 77.67
- EAF 41.62
- Support Level
- GLUE $8.94
- EAF $16.42
- Resistance Level
- GLUE $11.47
- EAF $18.88
- Average True Range (ATR)
- GLUE 0.88
- EAF 1.73
- MACD
- GLUE 0.18
- EAF -0.89
- Stochastic Oscillator
- GLUE 89.43
- EAF 4.11
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.